Veraxa Biotech Stock: Post-Merger Valuation Does Not Match The Risk (NASDAQ:VRXA)
· seekingalpha.com
Veraxa Biotech (VRXA) rated Sell: shares look overvalued post‑SPAC. The pipeline’s fragility is pronounced. See here for more details.
Veraxa Biotech AG ( VRXA ) arrived on the NASDAQ just a few days ago (June 11th), but not through a generic IPO. They were created through a SPAC merger. Veraxa...